What is the future of targeted therapy in rheumatology: biologics or small molecules?
about
Importance of the novel organic cation transporter 1 for tyrosine kinase inhibition by saracatinib in rheumatoid arthritis synovial fibroblasts.Significance of Interleukin-6/STAT Pathway for the Gene Expression of REG Iα, a New Autoantigen in Sjögren's Syndrome Patients, in Salivary Duct Epithelial Cells.Discovery of new small molecules inhibiting 67 kDa laminin receptor interaction with laminin and cancer cell invasionRheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritisIncreased Prevalence of Human Polyomavirus JC Viruria in Chronic Inflammatory Rheumatic Diseases Patients in Treatment with Anti-TNF α: A 18 Month Follow-Up Study.Targeting the PDGF-B/PDGFR-β Interface with Destruxin A5 to Selectively Block PDGF-BB/PDGFR-ββ Signaling and Attenuate Liver FibrosisSafety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.JAK inhibition in inflammatory bowel disease.Targeting the complement cascade: novel treatments coming down the pike.The Role of Transporters in the Toxicity of Chemotherapeutic Drugs: Focus on Transporters for Organic Cations.Biosimilar biologic drugs: a new frontier in medical care.A human tissue-based functional assay platform to evaluate the immune function impact of small molecule inhibitors that target the immune system.Tamarixinin A Alleviates Joint Destruction of Rheumatoid Arthritis by Blockade of MAPK and NF-κB Activation.Open questions in autoimmunity: discussions from the 2013 Controversies in Rheumatology and Autoimmunity Meeting.Tofacitinib: A Review in Rheumatoid Arthritis.Peptides as Therapeutic Agents for Dengue Virus.Calvarial Defect Healing Induced by Small Molecule Smoothened Agonist.Interleukin-6/STAT pathway is responsible for the induction of gene expression of REG Iα, a new auto-antigen in Sjögren׳s syndrome patients, in salivary duct epithelial cells.Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models.Therapeutic Potential of Small Molecule Inhibitors.Next generation of small molecules in inflammatory bowel disease.Computer-aided design of amino acid-based therapeutics: a review.Case report: successful treatment of refractory SAPHO syndrome with the JAK inhibitor tofacitinib.Total Joint Arthroplasty in Patients with Inflammatory Rheumatic DiseasesDesign, synthesis and evaluation of ()-3-(7-(methyl(7-pyrrolo[2,3-]pyrimidin-4-yl)amino)-5-azaspiro[2.4]heptan-5-yl)-3-oxopropanenitrile as a JAK1-selective inhibitorThe small molecule NSM00191 specifically represses the TNF-α/NF-кB axis in foot and ankle rheumatoid arthritis
P2860
Q30313218-2A9AC1F5-2E71-4119-860C-15E93B39E2F3Q36060629-1B672886-95B6-4A1E-A963-C079C60E0FB0Q36228519-27160D45-03C8-4960-8AEA-CB0CE37FE7F1Q36673061-A90D68C4-BA09-4BAB-948C-FC7F71B34579Q36885632-382A3B73-33A8-4466-B147-8E9816BCE8D8Q37009087-3B185F5A-94B3-4BCA-A181-59152DCD0DE3Q38305522-6D22E9B9-844A-4274-ABBD-F97C1EAB6B26Q38761142-C5660E2A-1FE5-4129-AF9B-F7DDC523790BQ38850489-13F973E6-D2C3-44E2-9F73-F4AA5763E45DQ38888345-6CDD1A23-33E8-461D-9284-83B4CBC4E047Q39200937-4AA53858-B69C-4EEA-88F9-C15194E6B965Q40129952-9A136625-0643-4A3C-B400-7F141FBFA704Q41438198-CB5608DE-3139-45E3-AC28-79944C53B41AQ42356893-2DE5929A-D19F-4614-A794-672DF5A1C3B5Q43280727-2EA82866-DC5C-4AC6-8AA5-7619CF57C94BQ45323856-D52C83E8-874C-4C09-A32D-BD0B98BA47BDQ45984571-FA3CC5DC-E652-4E2B-9D1A-A77370AD1193Q46974371-B054C36D-B65C-4DB1-A28F-916C3E1BB4BEQ47141265-C04C44C1-1830-4C97-A06E-71A8C6735B69Q47598540-97E8E49A-9085-4A48-9C75-E5E64B538A89Q55007993-320CC668-7069-469A-A41B-EF45EF837F76Q55315041-71CF21FE-F223-472E-BD4B-736E4A5BB2F3Q55426864-DD94C0DB-5C99-4440-92F6-42A7B51D46EFQ57176362-AE867414-20FE-493F-B94C-52FD5EF4B7FFQ57557905-1B250A74-F708-475E-800D-095E4029CB88Q58786220-6D3BF422-674A-4E5F-A5B7-0E8A8C10D789
P2860
What is the future of targeted therapy in rheumatology: biologics or small molecules?
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
What is the future of targeted therapy in rheumatology: biologics or small molecules?
@ast
What is the future of targeted therapy in rheumatology: biologics or small molecules?
@en
type
label
What is the future of targeted therapy in rheumatology: biologics or small molecules?
@ast
What is the future of targeted therapy in rheumatology: biologics or small molecules?
@en
prefLabel
What is the future of targeted therapy in rheumatology: biologics or small molecules?
@ast
What is the future of targeted therapy in rheumatology: biologics or small molecules?
@en
P2860
P356
P1433
P1476
What is the future of targeted therapy in rheumatology: biologics or small molecules?
@en
P2093
László Kovács
Péter Gergely
P2860
P2888
P356
10.1186/1741-7015-12-43
P407
P577
2014-03-13T00:00:00Z
P5875
P6179
1010266904